Equities

Gelteq Ltd

GELS:NAQ

Gelteq Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.53
  • Today's Change-0.72 / -32.00%
  • Shares traded178.77k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.55m
  • Incorporated2017
  • Employees--
  • Location
    Gelteq LtdLevel 4, 100 Albert RoadMELBOURNE 3205AustraliaAUS
  • Phone+61 39087-3990
  • Websitehttps://www.gelteq.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunoprecise Antibodies Ltd17.28m-19.80m13.55m102.00--0.5446--0.7843-0.7482-0.74820.66060.8630.35466.126.16---40.63-26.70-46.68-30.3148.2156.13-114.58-85.720.8189-134.720.3289--18.6517.54-2.32--16.71--
Onconetix Inc1.46m-53.12m14.60m12.00------9.97-104.90-104.902.8950.920.03283.455.30121,979.20-119.09---215.11---57.21---3,629.24--0.091-11.870.2984-------176.78------
Bright Green Corp0.00-9.92m15.33m5.00--1.54-----0.0538-0.05380.000.05190.00----0.00-47.48---72.55--------------0.0494------52.54------
Talphera Inc398.00k-13.70m15.46m15.00--1.21--38.85-0.6353-0.63230.01850.74910.0187----26,533.33-64.37-22.60-78.11-28.55-----3,443.22-714.87----0.00-----21.26-119.16---34.33--
Cumberland Pharmaceuticals, Inc.37.79m-10.38m16.81m91.00--0.6414--0.445-0.7328-0.73282.671.870.45010.86433.17415,225.80-12.35-7.03-17.75-9.5282.5879.95-27.45-17.641.26-38.850.382---5.856.15-12.73---36.17--
TherapeuticsMD Inc996.00k-4.83m17.30m1.00--0.6252--17.37-0.4348-0.55380.08892.400.0212--0.5048996,000.00-10.31-53.35-13.13-111.6145.0886.67-485.34-236.57----0.00---98.14-39.53-816.85------
Cara Therapeutics Inc11.00m-111.08m18.70m55.00--1.61--1.70-2.04-2.040.20170.21150.10631.102.10199,927.30-107.38-35.76-132.61-40.8274.66---1,010.20-162.104.48--0.00---49.929.26-38.65--100.66--
Marinus Pharmaceuticals Inc30.26m-149.24m19.00m165.00------0.6278-2.66-2.660.5391-0.86140.210.75086.98183,412.10-103.54-49.64-131.60-57.7690.64---493.14-518.962.15-11.806.10--21.63---613.59--7.47--
Cyclo Therapeutics Inc1.13m-20.74m21.24m8.00------18.75-0.9104-0.91040.0474-0.17850.2420.400213.16141,553.80-443.08-132.22---215.1791.5690.37-1,831.29-1,114.040.4283-------21.761.25-29.81---3.95--
Gelteq Ltd0.00-1.55m21.24m----1.49-----0.1617-0.16170.001.51------------------------1.38-32.410.0605-------72.77------
China Health Industries Holdings, Inc.95.95k-1.36m21.30m32.00------221.99-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
Nexgel Inc5.01m-3.39m21.32m19.00--4.78--4.26-0.5722-0.57220.84640.65890.49423.036.44263,631.60-35.74-44.61-48.15-56.1923.745.02-72.33-180.980.8135--0.1992--99.6613.0633.48------
Polypid Ltd0.00-24.70m23.81m59.00--10.49-----9.65-9.650.000.33370.00----0.00-107.89-76.92-164.39-89.61-----------24.210.8425------39.67---42.34--
Tonix Pharmaceuticals Holding Corp12.46m-149.01m25.89m103.00--0.0339--2.08-110.99-110.996.164.280.10830.8436--120,951.50-129.55-59.46-157.22-65.9221.59---1,196.12-5,126.730.7181--0.1678------0.1874--320.57--
Natural Alternatives International, Inc.113.80m-7.22m26.72m296.00--0.3235--0.2348-1.23-1.2319.3813.320.76763.969.52384,445.90-4.872.33-5.612.806.0314.24-6.342.061.59-10.210.13260.00-26.11-3.82-386.16---10.75--
BioXcel Therapeutics Inc2.40m-107.83m27.09m74.00------11.28-3.56-3.560.074-1.840.02340.59413.8732,472.97-104.93-74.57-150.29-84.0643.07---4,487.39-32,300.742.25-10.103.59--268.00---8.02---43.26--
Data as of Nov 13 2024. Currency figures normalised to Gelteq Ltd's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.